DJIA 18,010.68 -115.44 -0.64%
NASDAQ 5,070.03 -27.95 -0.55%
S&P 500 2,107.39 -13.40 -0.63%
market minute promo

Merck & Co., Inc. (NYSE: MRK)

60.89 1.19 (1.99%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

MRK $60.89 1.99%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $59.88
Previous Close $59.70
Daily Range $59.47 - $61.12
52-Week Range $52.49 - $63.62
Market Cap $172.0B
P/E Ratio 15.59
Dividend (Yield) $1.80 (3.0%)
Ex-Dividend Date
Dividend Pay Date
06/11/15
07/08/15
Volume 19,970,479
Average Daily Volume 10,389,229
Current FY EPS $3.43

Sector

Healthcare

Industry

Drug Makers

Merck & Co., Inc. (MRK) Description

A global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of innovative products to improve human and animal health. Website: http://www.merck.com/

News & Commentary

Gilead's Sustainable Competitive Advantage

Gilead Sciences' long-term growth is being doubted by the Street because of the uncertainty surrounding the hep C market going forward. The biotech's top notch CEO John Martin, however, should be reason enough for investors to believe that company's best days lie ahead. Here's why.

Dow Jones (DJIA) Today: Merck (MRK) Leads The Day Higher, Goldman Sachs Group (GS) Lags

Is A Big Acquisition Is Due For Pfizer?

Weekly Market Wrap: May 29, 2015

ASCO '15: Merck, Bristol Drugs Boost Immune System to Kill Broad Swath of Cancer Types

Is A Big Acquisition Is Due For Pfizer?

Short Sellers More Selective on Big Pharma Stocks

Merck/J&J Get CHMP Backing for Simponi's Expanded Use - Analyst Blog

Merck/J&J Get CHMP Backing for Simponi's Expanded Use - Analyst Blog

Cancer Drug Spending Breaks Through $100B With Immunotherapy Still In Its Infancy

Daily Dividend Report: MRK, DE, ESS, STR, DSW, MOV

See More MRK News...

MRK's Top Competitors

MRK $60.89 (1.99%)
Current stock: MRK
JNJ $100.14 (-1.00%)
Current stock: JNJ
NVS $102.73 (-1.46%)
Current stock: NVS
RHHBY $38.46 (2.83%)
Current stock: RHHBY